Toni K. Choueiri, MD is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. He is the Medical Director, International Strategic Initiatives at DFCI and past President of the Medical Staff at DFCI. He has received multiple national and international awards, is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania, and currently serves as an American Society of Clinical Oncology (ASCO) Board member (2024-2028).

Dr. Choueiri is interested in developing novel experimental therapies and biomarkers in GU malignancies, including renal cell carcinoma (RCC). Dr. Choueiri and colleagues reported trial results that led to the approval of several novel cancer therapies that have defined and evolved the treatment of RCC. His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy.

Dr. Choueiri has received research funding from the NCI, the Department of Defense (DOD), and industry partners. His work has been published in prestigious journals such as the New England Journal of Medicine, The Lancet, Science, Nature, and Nature Medicine. He has over 850 PubMed-indexed publications, has an H-Score of 149 (Google scholar, April 1 2025), and is the lead investigator of multiple national and international clinical trials in oncology.